TGFB1 and renal carcinoma: In vivo experiments further confirmed that OAV-Decorin can change the composition of ECM in renal cancer tissues, inhibit the expression of TGF-β, increase the infiltration of OAV and CAR-T in tumor tissues, and reduce the inhibition of CAR-T cells in the immunosuppressive microenvironment, thus achieving the antitumor effect.